GLP Watchdog
FDA-Approved MedicationUpdated September 2026

Mounjaro Guide

Mounjaro is the brand-name formulation of tirzepatide FDA-approved for type 2 diabetes, manufactured by Eli Lilly. It is prescribed weekly by injection and has become extremely popular off-label for weight loss given its superior efficacy data. Like Ozempic, Mounjaro is often prescribed for weight management while awaiting broader obesity indications.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed

At a Glance

Generic NameTirzepatide
Brand NamesMounjaro
FDA StatusFDA-approved for type 2 diabetes (May 2022). Off-label use for weight loss is common; the weight management indication is covered by Zepbound (FDA-approved November 2023).[1]
Approval DateMay 13, 2022[1]

How Mounjaro Works

Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon. The same pathways simultaneously reduce appetite, slow gastric emptying, and appear to act directly on fat cells — producing the highest weight loss rates of any approved medication.[2][3]

Dosing Schedule

Mounjaro uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+15mg/week (max)

Side Effects

Common: nausea (12–18%), diarrhea (13–16%), vomiting (5–9%), constipation (5–7%), decreased appetite, abdominal pain, injection site reactions. Side effects typically improve after the first 4–8 weeks. Serious (rare): pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury.[1][2]

Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].

Clinical Trial Results

In the SURPASS-2 trial, Mounjaro (tirzepatide 15mg) reduced HbA1c by 2.46 percentage points and produced 12.4 lbs more weight loss than semaglutide 1mg. Sub-analyses showed 41% of participants achieved an HbA1c below 5.7% — essentially normal blood sugar levels.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Mounjaro

Sellers in our register that will dispense tirzepatide, or a compounded version of it, after an online consultation — shipped to your door.

6.1/ 10
Verified partner

DudeMeds

Best for: compounded semaglutide at $175/month

★★★☆☆3.1/5

Editorial score · methodology

$175/mo
CompoundedSemaglutideTirzepatideNAD+
Get StartedRead full DudeMeds review →
8.2/ 10

Effecty

Best for: moving between compounded and brand without changing seller

★★★★☆4.1/5

Editorial score · methodology

$60/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Effecty review →
7.6/ 10

altRX

Best for: semaglutide from $1149/month

★★★★☆3.8/5

Editorial score · methodology

$149/mo
CompoundedSemaglutideTirzepatideLegitScript VerifiedFDA Warning
Get StartedRead full altRX review →
7.3/ 10

Ark Health

Best for: moving between compounded and brand without changing seller

★★★★☆3.7/5

Editorial score · methodology

$125/mo
CompoundedSemaglutideTirzepatideSermorelin
Get StartedRead full Ark Health review →
7.2/ 10

Levity

Best for: semaglutide from $1199/month

★★★★☆3.6/5

Editorial score · methodology

$1,199/mo
BrandSemaglutideTirzepatideFDA Warning
Get StartedRead full Levity review →
6.9/ 10

Noom

Best for: coaching bundled into the price rather than sold separately

★★★★☆3.5/5

Editorial score · methodology

$79/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Noom review →

Cost Comparison

Mounjaro cost & pricing →Savings & coupons →Side effects →Dosing & titration →How to get it →Storage & handling →Alternatives →Manufacturer coupon →

What each seller in the register charges to start on a compounded GLP-1, cheapest at the top. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], and the rules have historically loosened further for any molecule sitting on the FDA Drug Shortage List[5]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[6]. What you actually pay moves with your dose and with whatever promotion happens to be running.

ProviderStarting PriceLink
Noom$349/moVisit
Vital Edge$835/moVisit
NowPatient$1,069/moVisit
altRX$1,249/moVisit
Levity$1,299/moVisit
Effecty$1,300/moVisit
DudeMeds$1,350/moVisit
Eve$1,399/moVisit
Ark Health$1,499/moVisit
Better U Care$1,695/moVisit

Mounjaro Head-to-Head Comparisons

Short verdict pages setting Mounjaro against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.

Mounjaro vs Ozempic
Two diabetes drugs prescribed off-label for weight. SURPASS-2 compared them directly at 40 weeks (11.2 kg against 5.7 kg), but only Ozempic has finished a cardiovascular outcomes trial.
Last verified 2026-05-27
Mounjaro vs Zepbound
One molecule from one manufacturer under two names. The label is the whole difference: diabetes on one side, obesity and sleep apnea on the other, at identical doses and identical cash prices.
Last verified 2026-05-27
Mounjaro vs Wegovy
Mounjaro is labeled for diabetes; Wegovy for weight and cardiac risk. Head to head the tirzepatide molecule wins on weight, but you cannot get it under this brand without diabetes.
Last verified 2026-05-27
Mounjaro vs Trulicity
Two weekly Lilly injections for diabetes. Mounjaro is the stronger molecule on every measure; Trulicity holds the finished heart trial, the pediatric label and the kidney evidence.
Last verified 2026-05-28
Mounjaro vs Foundayo
Foundayo is Lilly's daily pill, approved for weight in April 2026 on -11.1% in ATTAIN-1. Mounjaro is the same company's weekly injection, labeled for diabetes only. A pill against a shot.
Last verified 2026-05-28
Mounjaro vs Saxenda
Mounjaro is Lilly's weekly tirzepatide, labeled for diabetes. Saxenda is Novo's daily liraglutide, labeled for weight. Different molecules, different diseases, different schedules, and readers compare them anyway.
Last verified 2026-05-28

See all drug-vs-drug verdicts.

Mounjaro Patient Questions, Answered

Questions people actually asked about Mounjaro in named subreddits, each answered from the published trial data.

The 10 Tirzepatide Questions People Actually Ask, Answered From the Trials
10 questions · 11 PubMed citations
Last verified 2026-05-27
GLP-1 Coverage: the 10 Questions People Ask After a Denial
10 questions · 12 PubMed citations
Last verified 2026-05-28
Injecting a GLP-1: 10 Technique Questions, Answered
10 questions · 11 PubMed citations
Last verified 2026-05-28

Mounjaro Reference Cards

One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.

Mounjaro Step-Up Cheat Sheet: When to Climb
Mounjaro and Zepbound are the same molecule on the same six-dose ladder, and that similarity hides the difference that matters: Mounjaro is licensed for type 2 diabetes, so what decides whether you climb is your blood sugar rather than the scale. This page gives the ladder, the checkpoint logic for advancing or holding, the separate 10 mg ceiling for younger patients, and the symptoms that mean stop.
5 min read · Last verified 2026-05-27
GLP-1 Injection Sites: Rotation, Technique and the Lump to Avoid
Every weekly GLP-1 permits the same three injection sites and every one of them tells you to move around. The reason is a lump called lipohypertrophy — thickened fat that soaks up the drug at an unpredictable rate. When absorption becomes erratic so does appetite suppression, and a stalled month gets blamed on the dose when the cause is a favorite square inch of belly.
4 min read · Last verified 2026-05-28
Switching Between GLP-1s: Why You Start at the Bottom Again
Switching is common — a formulary changes, side effects bite, or you reach the top of a ladder with weight still to lose — and no label tells you how to do it. The rule that surprises people is that you go back to the bottom even though you have been on a GLP-1 for a year. Tolerating one of these drugs does not buy you tolerance of another, because they do not act on the same receptors.
5 min read · Last verified 2026-05-28

Ranked PubMed Studies on Mounjaro

The peer-reviewed studies on Mounjaro and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.

The 10 Tirzepatide Trials That Built the Case (2026)
Tirzepatide is the only dual GIP and GLP-1 agonist with a finished phase 3 obesity program, and the ten trials below are why it currently sits at the top of the evidence. They cover the pivotal result, what happens in diabetes, what happens when you stop, the direct comparison against semaglutide, and two indications — sleep apnea and heart failure — that have nothing to do with the scale.
10 ranked papers · Last verified 2026-08-16

Related Research on Mounjaro

Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.

Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap
Eructation runs under 1% on placebo against 7% on Wegovy: a sevenfold difference, and the widest relative gap in the adverse-reactions table. Reflux is a much smaller increase than people expect.
6 min read3 citations
Constipation on a GLP-1: What the Labels Report and What Actually Helps
The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. Here is why it outlasts the nausea, and where the confident advice online runs ahead of the evidence.
6 min read9 citations
GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted
Two labeled warnings that are not the same kind of problem. Gallbladder disease tracks with rapid weight loss and is well counted; pancreatitis is rarer, was an exclusion criterion in the pivotal trials, and the database studies disagree.
12 min read19 citations
GLP-1 Hair Loss and Muscle Loss: What Was Measured
Hair shedding and lean-mass loss both appear in the trial record, and both are mostly consequences of losing weight quickly rather than of the drug. That is reassuring about mechanism and not reassuring about outcome, and this holds both.
11 min read15 citations
How Long Do Semaglutide and Tirzepatide Side Effects Last?
What predicts side effects is where you are on the ladder, not how many weeks you have been taking it. Both labels place the nausea and diarrhea during escalation, and how long any single dose keeps working comes down to half-life: roughly seven days for semaglutide, roughly five for tirzepatide.
11 min read8 citations
GLP-1 Telehealth Cancellation and Refund Policies
Can you cancel a GLP-1 telehealth plan any time, and do you get a refund? We read the terms of every seller we track: who lets you stop monthly, who locks you in, and who refunds nothing once medication ships.
6 min read1 citation

Frequently Asked Questions

FDA-approved for type 2 diabetes (May 2022). Off-label use for weight loss is common; the weight management indication is covered by Zepbound (FDA-approved November 2023).
What you pay for Mounjaro turns on who is selling it and in what form. Uninsured, the branded product runs roughly $1,000 to $1,600 a month; compounded versions through telehealth sellers usually land between $129 and $400. The table above carries the current figures from our register. Before you commit, check whether a manufacturer savings program applies to you.
Common: nausea (12–18%), diarrhea (13–16%), vomiting (5–9%), constipation (5–7%), decreased appetite, abdominal pain, injection site reactions. Side effects typically improve after the first 4–8 weeks. Serious (rare): pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury.
Mounjaro is prescription-only, so someone licensed has to write it — your own doctor, an endocrinologist, or one of the telehealth sellers above. For compounded versions the telehealth route is usually both quicker and cheaper out of pocket than a traditional pharmacy.
Sources & methodology — as of September 2026
  1. 1.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SURPASS-2 Trial — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (Frías JP et al.)— New England Journal of Medicine.PMID: 34170647.
  3. 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary

The words sellers use, defined. Tap any term.